Roger Tell - Isofol Medical Chief Medical Officer, Chief Scientific Officer

All Insiders . Sweden . 
Stock . Isofol Medical AB . Stakeholders . Insider . Roger Tell
ISOFOL Stock  SEK 2.95  0.05  1.67%   

Insider

Roger Tell is Chief Medical Officer, Chief Scientific Officer of Isofol Medical AB since 2019.
Tenure 5 years
Phone46 3 17 97 22 80
Webhttps://isofolmedical.com

Isofol Medical Management Efficiency

The company has return on total asset (ROA) of (0.3605) % which means that it has lost $0.3605 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6945) %, meaning that it generated substantial loss on money invested by shareholders. Isofol Medical's management efficiency ratios could be used to measure how well Isofol Medical manages its routine affairs as well as how well it operates its assets and liabilities.
Isofol Medical AB has accumulated 110 K in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. Isofol Medical AB has a current ratio of 1.19, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Isofol Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Isofol Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Isofol Medical AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Isofol to invest in growth at high rates of return. When we think about Isofol Medical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Henrik MScBavarian Nordic
58
Lars UttenthalBioPorto
N/A
Russell ThirskBavarian Nordic
N/A
Christopher BirdBioPorto
N/A
Niels KristensencBrain AS
N/A
Nis KruseBioPorto
N/A
JeanChristophe MayBavarian Nordic
56
Neil CPABioPorto
55
Paul MScBavarian Nordic
56
Anthony PareBioPorto
60
EjvindgensencBrain AS
N/A
Rolf SrensenBavarian Nordic
N/A
Jennifer ZondermanBioPorto
N/A
Tony SummerlincBrain AS
N/A
Laurence MoerloozeBavarian Nordic
59
Gry LarsenBioPorto
N/A
Anu KernsBavarian Nordic
51
Isofol Medical AB , a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden. Isofol Medical operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 12 people. Isofol Medical AB (ISOFOL) is traded on Stockholm Exchange in Sweden and employs 15 people.

Management Performance

Return On Equity-0.69
Return On Asset-0.36

Isofol Medical AB Leadership Team

Elected by the shareholders, the Isofol Medical's board of directors comprises two types of representatives: Isofol Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Isofol. The board's role is to monitor Isofol Medical's management team and ensure that shareholders' interests are well served. Isofol Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Isofol Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
ParOla Mannefred, Chairman of the Board
Gustaf MSc, CFO CEO
Magnus Bjorsne, Director
Roger Tell, Chief Medical Officer, Chief Scientific Officer
Karin Ganlov, Senior Medical Director
Paula Boultbee, Director
Anna Belfrage, Director
Jarl MD, CEO MD
Robert Marchesani, Director
Alain Herrera, Director
Jarl Jungnelius, Chief Executive Officer, Director
Roger MD, Chief Officer
Jenny Sundqvist, Chief Officer
Gustaf Albert, Chief Financial Officer

Isofol Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Isofol Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.69
Return On Asset-0.36
Operating Margin(13.09) %
Current Valuation(42.41 M)
Shares Outstanding161.52 M
Shares Owned By Insiders25.71 %
Shares Owned By Institutions12.47 %
Price To Book0.65 X
Price To Sales7.45 X
Revenue22.41 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Other Information on Investing in Isofol Stock

Isofol Medical financial ratios help investors to determine whether Isofol Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Isofol with respect to the benefits of owning Isofol Medical security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY